-
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., Patrick, S.M. 2010. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst), 9: 745–753.
-
Dela Cruz, C.S., Tanoue, L.T., Matthay, R.A. 2011. Lung cancer: Epidemiology, etiology, and prevention. Clinics in Chest Medicine, 32(4): 605–644.
-
Fadejeva, I., Olschewski, H., Hrzenjak, A. 2017. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget, 8(70): 115754–115773.
-
Fennell, D.A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D.C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., Ferry, D. 2016. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 44: 42–50.
-
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G. 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31(15): 1869–1883.
-
Gąsiorkiewicz, B.M., Koczurkiewicz-Adamczyk, P., Piska, K., Pękala, E. 2021. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer. Investigation New Drugs, 39: 538–563.
-
He, Y., Chen, D., Yi, Y., Zeng, S., Liu, S., Li, P., Xie, H., Yu, P., Jiang, G., Liu, H. 2020. Histone deacetylase inhibitor sensitizes ERCC1-high non-small-cell lung cancer cells to cisplatin via regulating miR-149. Molecular Therapy – Oncolytics, 17: 448–459.
-
Hu, C., Zhang, M., Moses, N., Hu, C.-L., Polin, L., Chen, W., Jang, H., Heyza, J., Malysa, A., Caruso, J.A., Xiang, S., Patrick, S., Stemmer, P., Lou, Z., Bai, W., Wang, C., Bepler, G., Zhang, X.M. 2020. The USP10-HDAC6 axis confers cisplatin resistance in non-small cel lung cancer lacking wild-type p53. Cell Death & Disease, 11: 1–18.
-
Lan, D., Wang, L., He, R., Ma, J., Bin, Y., Chi, X., Chen, G., Cai, Z. 2018. Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. American Journal of Translational Research, 10: 1295–1309.
-
O’Byrne, K.J., Barr, M.P., Gray, S.G. 2011. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers (Basel), 3(1): 1426–1453.